Syndax Pharmaceuticals Inc Encouraging Real World Maintenance and PK Data at ASCO

Goldman Sachs maintains a Buy rating on Syndax Pharmaceuticals following encouraging real-world maintenance survival data (90% 2-year OS) and favorable PK data presented at ASCO. The firm highlights Revuforj's competitive advantages in ease of administration and efficacy over rival Komzifti.

Key Takeaways

• 1.Real-world data for revumenib (Revuforj) in maintenance therapy post-transplant showed a 90% 2-year overall survival rate, nearly doubling the historical benchmark of 51%.
• 2.PK data suggests revumenib has a superior administration profile compared to competitor Komzifti, as it can be taken with PPIs and without fasting requirements.
• 3.Early cross-trial comparisons for revumenib in combination therapies show numerically superior efficacy (ORR 88% vs 64%) and similar safety profiles compared to ziftomenib.

Table of Contents

• Key takeaways
• Valuation and risks
• Disclosure Appendix
• Reg AC
• GS Factor Profile
• M&A Rank
• Quantum
• Disclosures
• Company-specific regulatory disclosures
• Distribution of ratings/investment banking relationships
• Price target and rating history chart(s)
• Target price history table(s)
• Regulatory disclosures
• Global product; distributing entities
• General disclosures